Immunovant’s IMVT-1402 generated a market-moving early readout in difficult-to-treat rheumatoid arthritis. The company disclosed “compelling” initial Phase IIb open-label results for patients with inadequate response to at least two prior advanced therapies, including TNF and JAK inhibitors. Management said 16-week outcomes showed strong response rates across ACR20, ACR50 and ACR70 assessments, while further processing of the data and U.S. FDA discussions remain ahead. The trial is still ongoing, limiting conclusions to interim signals. The update matters for competition in RA by adding another FcRn-targeting mechanism as developers seek differentiation in autoimmune indications with high unmet need.